Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 1.0%
Thu, 12 Sep 9:46

Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 1.0%Image source: alexsl/www.istockphoto.com

Aurobindo Pharma share price has zoomed 4% and is presently trading at Rs 1,570.6.

Meanwhile, the BSE HEALTHCARE index is at 44,231.6 (up 1.0%).

Among the top gainers in the BSE HEALTHCARE index today are FDC (up 8.4%) and HIKAL CHEMIC (up 4.4%).

SUVEN PHARMACEUTICALS (down 1.0%) and Natco Pharma (down 0.4%) are among the top losers today.

Over the last one year, Aurobindo Pharma has moved up from Rs 867.7 to Rs 1,570.6, registering a gain of Rs 702.9 (up 81.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,436.8 to 44,231.6, registering a gain of 55.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 128.3%), SUVEN PHARMACEUTICALS (up 127.6%) and GRANULES INDIA (up 118.8%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 81,779.6 (up 0.3%).

The top gainers among the BSE Sensex today are Tata Steel (up 1.9%) and MUNDRA PORT & SEZ (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 25,010.0 (up 0.4%). Tata Steel and Shriram Transport are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 67,127.1 to 81,779.6, registering a gain of 14,652.5 points (up 21.8%).

Aurobindo Pharma Financial Update...

Aurobindo Pharma net profit grew 60.6% YoY to Rs 9,196 million for the quarter ended June 2024, compared to a profit of Rs 5,725 million a year ago. Net sales rose 10.5% to Rs 75,670 million during the period as against Rs 68,505 million in April-June 2023.

For the year ended March 2024, Aurobindo Pharma reported 64.4% increase in net profit to Rs 31,690 million compared to net profit of Rs 19,277 million during FY23. Revenue of the company grew 16.7% to Rs 290,019 million during FY24.

The current Price to earnings ratio of Aurobindo Pharma, based on rolling 12 month earnings, stands at 26.0.


Equitymaster requests your view! Post a comment on "Aurobindo Pharma Gains 4%; BSE HEALTHCARE Index Up 1.0%". Click here!